ValueScreener company report

ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG)

Name: ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) filed financial figures
Creator: ValueScreener

NASDAQ / Healthcare / Biotechnology

Share price

14.69 USD Market dataClose of Oct 15, 2026

Market capitalisation

1.37B USD Market dataClose of Oct 15, 2026

Market data: Oct 15, 2026
Filed accounts: FY2024, filed Apr 16, 2025
Ratios computed: Oct 15, 2026
Filed years: 3, FY2022 to FY2024

Four kinds of sourceSEC filingCompany statementMarket dataComputedWhat each means

SEC filingFiled with the SEC: Read from a statement the company filed with the SEC, with the form, fiscal year, filing date and accession beside it.
Company statementCompany statement: What the company says about itself in a filing: an 8-K item, the auditor, its own segment names.
Market dataMarket data: Prices, market value and what analysts publish, with the date they are as of.
ComputedComputed by ValueScreener: Worked out by us from the other three, with the inputs and the formula one press away. A score is a research output, not a rating or a recommendation.

Reading

1 of 10

Overview

What the business is, what it costs, and how it reads on four questions.

Market dataSEC filingComputed

Quality

Return on invested capital, after tax

n/a Computed

From the FY2024 filing

Why n/a

No annual statement of this kind is on file for this fiscal year.

Read quality

Financial strength

Debt to equity

n/a Computed

Why n/a

No annual statement of this kind is on file for this fiscal year.

Read financial strength

Valuation

Price to earnings

n/m Computed

FY2024 accounts, priced at the latest close

Why n/m

Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.

Read valuation

Cash generation

Free cash flow yield

-1.5% Computed

FY2024 accounts, priced at the latest close

Read cash generation

Revenue and net income, by fiscal year

Revenue Net income9 fiscal years; a year whose statement names no SEC filing is market data, and the table in Filings says which.

Named tests met: 0 of 30 Which tests

The business, and the score behind its five axes

The reading, in brief

Is it cheap

Free cash flow yield is -1.5% at the close of 2026-10-15 on FY2024 figures; the lines are 2.0%, 5.0% and 8.0%, set by convention, and this sits below the lowest.

Today, against the Biotechnology industry (427 companies), -1.5% sits at the 87th percentile; the middle half of that group runs from -91.4% to -6.2%.

Is it good

Return on invested capital for ASCENTAGE PHARMA GROUP INTERNATIONAL in FY2024: n/a. No annual statement of this kind is on file for this fiscal year.

Is it safe

Interest coverage for ASCENTAGE PHARMA GROUP INTERNATIONAL in FY2024: n/a. No operating income line is filed for this year.

Year by year against peers: Whether ASCENTAGE PHARMA GROUP INTERNATIONAL's gross margin stayed above the median of the Biotechnology industry, year by year. (FY2016 to FY2024, 9 fiscal years of ASCENTAGE PHARMA GROUP INTERNATIONAL with a comparable figure)
The direction: Which way ASCENTAGE PHARMA GROUP INTERNATIONAL's gross margin has moved, and how steadily. (FY2016 to FY2024, 9 filed years of ASCENTAGE PHARMA GROUP INTERNATIONAL)
What could explain it: What in ASCENTAGE PHARMA GROUP INTERNATIONAL's filed statements could explain the movements. (1 reading drawn from the statement lines ASCENTAGE PHARMA GROUP INTERNATIONAL filed)
What to check next: What to check next on ASCENTAGE PHARMA GROUP INTERNATIONAL, and where in its filings. (4 questions for ASCENTAGE PHARMA GROUP INTERNATIONAL)
In one paragraph: One paragraph on ASCENTAGE PHARMA GROUP INTERNATIONAL's returns, cash, balance sheet and price. (4 of sixteen figures read for ASCENTAGE PHARMA GROUP INTERNATIONAL)

These are AAPG’s filed figures. The research desk says what they mean, against peers and its own years, with what to check next.

Research AAPGPart of Serious. New accounts start with 30 days of Professional, free, no card.

2 of 10

What changed

The newest filing, what it moved, and when the next one is due.

SEC filingCompany statement

The newest accounts on file are the FY2024 annual report: 20-F, filed Apr 16, 2025, accession 0001213900-25-032599.

3 of 10

Quality

The returns the business earns on its capital, and the margins behind them.

SEC filingComputed

ASCENTAGE PHARMA GROUP INTERNATIONAL: returns on capital and margins, each with its source
Figure	Value, source and document
Return on invested capital, after tax Why n/a No annual statement of this kind is on file for this fiscal year.	n/a ComputedFY2024 20-F, filed Apr 16, 2025, 0001213900-25-032599
Return on equity Why n/a No annual statement of this kind is on file for this fiscal year.	n/a ComputedFY2024 20-F, filed Apr 16, 2025, 0001213900-25-032599
Return on capital employed, pre-tax Why n/a We do not hold this figure for this company, so there is nothing to show.	n/a ComputedFY2024 20-F, filed Apr 16, 2025, 0001213900-25-032599
Return on assets Why n/a We do not hold this figure for this company, so there is nothing to show.	n/a ComputedFY2024 20-F, filed Apr 16, 2025, 0001213900-25-032599
Gross margin	97.0% ComputedFY2024 20-F, filed Apr 16, 2025, 0001213900-25-032599
Operating margin Why n/a No operating income line is filed for this year.	n/a ComputedFY2024 20-F, filed Apr 16, 2025, 0001213900-25-032599
Net margin	-41.3% ComputedFY2024 20-F, filed Apr 16, 2025, 0001213900-25-032599

AAPG -41.3%

-85.4%-5.6%

Net margin: AAPG against the 5 companies named under Valuation context, each as filed for its own latest year. Placement only: no average is drawn.

4 of 10

Financial strength

What it owes against what it owns, and whether it can meet what falls due.

Market dataComputedCompany statement

ASCENTAGE PHARMA GROUP INTERNATIONAL: leverage, liquidity and distress, each with its source
Figure	Value, source and document
Debt to equity Why n/a No annual statement of this kind is on file for this fiscal year.	n/a ComputedStatement not held
Current ratio Why n/a No annual statement of this kind is on file for this fiscal year.	n/a ComputedStatement not held
Quick ratio Why n/a We do not hold this figure for this company, so there is nothing to show.	n/a ComputedFY2024 20-F, filed Apr 16, 2025, 0001213900-25-032599
Interest coverage Why n/a No operating income line is filed for this year.	n/a ComputedFY2024 20-F, filed Apr 16, 2025, 0001213900-25-032599
Altman Z-score Why n/a We do not hold this figure for this company, so there is nothing to show.	n/a ComputedClose of Oct 15, 2026 · FY2024 20-F, filed Apr 16, 2025, 0001213900-25-032599
Net debt	-622.6M ComputedFY2021 market data, supplied Oct 15, 2026, no SEC filing named, accession n/a

Total assets Total liabilities Shareholders’ equity

The balance sheet, line by line

Financial health

What ASCENTAGE PHARMA GROUP INTERNATIONAL owned and owed at the end of fiscal 2021, from a copy of its balance sheet that names no SEC filing (market data).

ASCENTAGE PHARMA GROUP INTERNATIONAL: balance sheet position
Total assets	2.94B Market dataFY2021 market data, supplied Oct 15, 2026, no SEC filing named
Total liabilities	1.71B Market dataFY2021 market data, supplied Oct 15, 2026, no SEC filing named
Shareholders' equity	1.23B Market dataFY2021 market data, supplied Oct 15, 2026, no SEC filing named
Cash	1.71B Market dataFY2021 market data, supplied Oct 15, 2026, no SEC filing named
Total debt	1.08B Market dataFY2021 market data, supplied Oct 15, 2026, no SEC filing named
Net debt	-622.6M
Current ratio	n/a
Debt to equity	n/a

Debt to equity: FY2021: The figures on this page are FY2024's, and for FY2024 this ratio is n/a; this FY2021 figure is from another year's balance sheet, so it is not printed beside them.
Current ratio: FY2021: The figures on this page are FY2024's, and for FY2024 this ratio is n/a; this FY2021 figure is from another year's balance sheet, so it is not printed beside them.
Interest cover: FY2021: The figures on this page are FY2024's, and for FY2024 this ratio is n/a; this FY2021 figure is from another year's balance sheet, so it is not printed beside them.

Read from the filed balance sheet for each year, with the income statement of the same year supplying operating profit where a ratio needs it. Nothing here is a view on whether this company is sound.

5 of 10

Valuation context

What the market charges for it, against its own record and companies like it.

Market dataSEC filingComputed

ASCENTAGE PHARMA GROUP INTERNATIONAL: what the market charges, each with its source
Figure	Value, source and document
Price to earnings Why n/m Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.	n/m ComputedClose of Oct 15, 2026 · FY2024 20-F, filed Apr 16, 2025, 0001213900-25-032599
P/E on trailing twelve months Why n/a A trailing figure needs 4 filed quarters with the dates they were filed on, and we hold 0 for this company. Nothing is drawn rather than a line built from fewer.	n/a ComputedClose of Oct 15, 2026 · Trailing four quarters, each as known on the day; the quarterly filings are listed under Filings
Price to book Why n/a We do not hold this figure for this company, so there is nothing to show.	n/a ComputedClose of Oct 15, 2026 · Statement not held
Price to sales	9.33x ComputedClose of Oct 15, 2026 · FY2024 20-F, filed Apr 16, 2025, 0001213900-25-032599
Enterprise value to EBIT Why n/a We do not hold this figure for this company, so there is nothing to show.	n/a ComputedClose of Oct 15, 2026 · FY2024 20-F, filed Apr 16, 2025, 0001213900-25-032599
Enterprise value to EBITDA Why n/a We do not hold this figure for this company, so there is nothing to show.	n/a ComputedClose of Oct 15, 2026 · FY2024 20-F, filed Apr 16, 2025, 0001213900-25-032599
Price to earnings over growth Why n/m Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.	n/m ComputedClose of Oct 15, 2026 · FY2024 20-F, filed Apr 16, 2025, 0001213900-25-032599
Diluted earnings per share Why n/a The FY2024 filing carries no diluted earnings per share we could read.	n/a FiledFY2024 20-F, filed Apr 16, 2025, 0001213900-25-032599
Graham number Why n/m Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.	n/m ComputedFY2024 20-F, filed Apr 16, 2025, 0001213900-25-032599

We publish no fair value or price target of our own. Value AAPG on your own assumptions in the DCF workbench, starting from the filed figures.

Its own record, and companies like it

Valuation

What the market charges for ASCENTAGE PHARMA GROUP INTERNATIONAL today, and the multiples it has carried. No value of ours: the figures are the filings’ and the market’s.

ASCENTAGE PHARMA GROUP INTERNATIONAL: valuation
Share price	14.69 USD
Market capitalisation	1.37B USD
Enterprise value to EBITDA	n/a
Graham number	n/m
Diluted earnings per share, FY2021	n/a

Price to earnings on trailing twelve months: A trailing figure needs 4 filed quarters with the dates they were filed on, and we hold 0 for this company. Nothing is drawn rather than a line built from fewer.

Companies like ASCENTAGE PHARMA GROUP INTERNATIONAL

Same industry (Biotechnology) and size band (Small, 300M to 2B), nearest in market value and net margin. Each of those counts equally, by how many of the companies considered sit between the two on it. Closest first: the order is likeness and nothing else.

6 of 10

Cash generation

Whether profit arrives as cash, and what is paid back to shareholders.

SEC filingComputed

ASCENTAGE PHARMA GROUP INTERNATIONAL: cash generation and what is paid out, each with its source
Figure	Value, source and document
Free cash flow yield	-1.5% ComputedClose of Oct 15, 2026 · FY2024 20-F, filed Apr 16, 2025, 0001213900-25-032599
Free cash flow	-135.6M CNY ComputedFY2024 20-F, filed Apr 16, 2025, 0001213900-25-032599
Free cash flow margin	-13.8% ComputedFY2024 20-F, filed Apr 16, 2025, 0001213900-25-032599
Dividend yield Why n/a We do not hold this figure for this company, so there is nothing to show.	n/a ComputedClose of Oct 15, 2026 · FY2024 20-F, filed Apr 16, 2025, 0001213900-25-032599
Payout ratio Why n/a We do not hold this figure for this company, so there is nothing to show.	n/a ComputedFY2024 20-F, filed Apr 16, 2025, 0001213900-25-032599

Free cash flow Net incomeProfit that arrives as cash stands level with net income; a gap year after year is worth reading about.

7 of 10

Filings

Every figure, the year it is for and the document it was read from.

SEC filingMarket data

The filed figures

Computed from the accounts this company filed with the SEC and, in a ratio with a price in it, the last close, dated on this page. Every filed figure below carries the fiscal year and the filing date its accounts were read from, and every blank carries the reason it is blank. Nothing here is a view on this company.

ASCENTAGE PHARMA GROUP INTERNATIONAL: the eight ratios, with the fiscal year and filing date behind each.
Figure	Value	Year	As of
	n/m	FY2024	Oct 15, 2026
n/m Not meaningful for this company, such as a P/E on negative earnings or a bank's EV/EBIT.
FormulaShare price / earnings per share. Where the filing states no earnings per share this listing can be priced on, which is every 20-F and 40-F filer because theirs is stated per ordinary share, it is market capitalisation / net income: the same multiple, undiluted. As ofThe close on Oct 15, 2026, over the filed figures of FY2024: a price is in this figure, and it moved after the filing. Form20-FFiledApr 16, 2025PeriodFY2024Accession0001213900-25-032599What we read from itIncome statementFY2024Open on SEC.gov, accession 0001213900-25-032599, leaves this page and opens in a new tab
	n/a	n/a	Oct 15, 2026
n/a No balance sheet for the latest filed year is on file, or the one on file reports no total assets.
FormulaMarket capitalisation / shareholders equity As ofThe close on Oct 15, 2026, over the filed figures of n/a: a price is in this figure, and it moved after the filing.
	n/a	FY2024	Oct 15, 2026
n/a Operating profit is zero or negative, so there is no profit for a buyer's price to be a multiple of.
Formula(Market capitalisation + total debt - cash) / operating income, or over the filing's own EBIT (income before tax + interest expense) where the filer tags no operating line, as Johnson & Johnson does not in any of its ten filed years. As ofThe close on Oct 15, 2026, over the filed figures of FY2024: a price is in this figure, and it moved after the filing. Form20-FFiledApr 16, 2025PeriodFY2024Accession0001213900-25-032599What we read from itIncome statementFY2024Open on SEC.gov, accession 0001213900-25-032599, leaves this page and opens in a new tab
	-1.5%	FY2024	Oct 15, 2026
FormulaFree cash flow per share / share price x 100 As ofThe close on Oct 15, 2026, over the filed figures of FY2024: a price is in this figure, and it moved after the filing. Form20-FFiledApr 16, 2025PeriodFY2024Accession0001213900-25-032599What we read from itCash flow statementFY2024Open on SEC.gov, accession 0001213900-25-032599, leaves this page and opens in a new tab
	n/a	FY2024	Apr 16, 2025
n/a No annual statement of this kind is on file for this fiscal year.
FormulaVendor trailing-twelve-month return on invested capital where one is published, which uses after-tax operating profit over total assets less current liabilities. Otherwise our own recompute: NOPAT / (shareholders equity + total debt - cash) x 100, where NOPAT is the filed operating profit after tax, or the filing's own EBIT after tax where the filer tags no operating line. As ofThe filing date of the statements below, for FY2024. Form20-FFiledApr 16, 2025PeriodFY2024Accession0001213900-25-032599What we read from itIncome statementFY2024Open on SEC.gov, accession 0001213900-25-032599, leaves this page and opens in a new tab
	n/a	FY2024	Oct 15, 2026
n/a The filed cash flow statement reports no dividend paid at all. That is not the same as a filed zero, and we will not read it as one.
FormulaCommon dividends paid in the latest filed year / market capitalisation x 100. n/a where the filing cannot support it: a special or first-year payment, a total that mixes preferred dividends, or a cash-flow statement over 15 months old. As ofThe close on Oct 15, 2026, over the filed figures of FY2024: a price is in this figure, and it moved after the filing. Form20-FFiledApr 16, 2025PeriodFY2024Accession0001213900-25-032599What we read from itCash flow statementFY2024Open on SEC.gov, accession 0001213900-25-032599, leaves this page and opens in a new tab
	n/a	n/a	n/a
n/a No annual statement of this kind is on file for this fiscal year.
FormulaTotal debt / shareholders equity As ofThe filing date of the statements below.
	n/a	n/a	n/a
n/a No annual statement of this kind is on file for this fiscal year.
FormulaCurrent assets / current liabilities As ofThe filing date of the statements below.
	9.33x	FY2024	Oct 15, 2026
FormulaMarket capitalisation / revenue As ofThe close on Oct 15, 2026, over the filed figures of FY2024: a price is in this figure, and it moved after the filing. Form20-FFiledApr 16, 2025PeriodFY2024Accession0001213900-25-032599What we read from itIncome statementFY2024Open on SEC.gov, accession 0001213900-25-032599, leaves this page and opens in a new tab
	n/m	FY2024	Oct 15, 2026
n/m Not meaningful for this company, such as a P/E on negative earnings or a bank's EV/EBIT.
FormulaPrice to earnings / the annual earnings growth rate, in percentage points As ofThe close on Oct 15, 2026, over the filed figures of FY2024: a price is in this figure, and it moved after the filing. Form20-FFiledApr 16, 2025PeriodFY2024Accession0001213900-25-032599What we read from itIncome statementFY2024Open on SEC.gov, accession 0001213900-25-032599, leaves this page and opens in a new tab
	n/a	FY2024	Oct 15, 2026
n/a No balance sheet for the latest filed year is on file, or the one on file reports no total assets.
Formula1.2 x working capital/assets + 1.4 x retained earnings/assets + 3.3 x EBIT/assets + 0.6 x market value of equity/total liabilities + 1.0 x revenue/assets As ofThe close on Oct 15, 2026, over the filed figures of FY2024: a price is in this figure, and it moved after the filing. Form20-FFiledApr 16, 2025PeriodFY2024Accession0001213900-25-032599What we read from itIncome statementFY2024Open on SEC.gov, accession 0001213900-25-032599, leaves this page and opens in a new tab
	n/a	FY2024	Apr 16, 2025
n/a No balance sheet for the latest filed year is on file, or the one on file reports no total assets.
FormulaAn eight-variable index of year-on-year changes in receivables, gross margin, asset quality, revenue, depreciation, overheads, leverage and accruals As ofThe filing date of the statements below, for FY2024. Form20-FFiledApr 16, 2025PeriodFY2024Accession0001213900-25-032599What we read from itIncome statementFY2024Open on SEC.gov, accession 0001213900-25-032599, leaves this page and opens in a new tabForm20-FFiledApr 16, 2025PeriodFY2024Accession0001213900-25-032599What we read from itCash flow statementFY2024Open on SEC.gov, accession 0001213900-25-032599, leaves this page and opens in a new tab
	n/a	FY2024	Apr 16, 2025
n/a The nine signals need complete filed accounts for two consecutive years and at least one input is not on file.
FormulaOne point each for: positive return on assets, positive operating cash flow, rising return on assets, operating cash flow above net income, falling leverage, rising current ratio, no new shares issued, rising gross margin, rising asset turnover. As ofThe filing date of the statements below, for FY2024. Form20-FFiledApr 16, 2025PeriodFY2024Accession0001213900-25-032599What we read from itIncome statementFY2024Open on SEC.gov, accession 0001213900-25-032599, leaves this page and opens in a new tabForm20-FFiledApr 16, 2025PeriodFY2024Accession0001213900-25-032599What we read from itCash flow statementFY2024Open on SEC.gov, accession 0001213900-25-032599, leaves this page and opens in a new tab

The figures are computed from the accounts for fiscal 2024, the newest full year on file. 3 filed fiscal years on record, FY2022 to FY2024, from SEC EDGAR. Prices as of Oct 15, 2026. Ratios recomputed Oct 15, 2026. Two facts, because a recompute is not a fresh quote.

The year and the filing date name the statement each figure’s accounts are read from, and they stand even where the figure itself could not be computed: the line beneath a blank says what that statement did not carry. A figure’s name opens its formula and the filings behind it; a statement that names no SEC filing has no filing date, and reads n/a.

Ten years of filed figures, year by year

Ten years of filed figures

9 fiscal years, FY2016 to FY2024. 3 read from the annual reports ASCENTAGE PHARMA GROUP INTERNATIONAL filed with the SEC, each naming its filing; the rest from statements that name none, which are market data. Amounts in CNY, as reported.

ASCENTAGE PHARMA GROUP INTERNATIONAL: revenue, earnings, free cash flow and returns, by fiscal year, with the filing each year was read from
Year	Revenue	Operating income	Net income	EPS, diluted	Free cash flow	Operating margin	Return on equity	Filing
FY2024	980.6M	-330.8M	-405.4M	n/a	-135.6M	n/a	n/a	20-F, Apr 16, 20250001213900-25-032599
FY2023	222.0M	-836.8M	-925.6M	n/a	-772.2M	n/a	n/a	20-F, Apr 16, 20250001213900-25-032599
FY2022	209.7M	-834.4M	-882.9M	n/a	-857.2M	n/a	n/a	20-F, Apr 16, 20250001213900-25-032599
FY2021	27.9M	-869.8M	-782.4M	-49.12	-1.04B	-3116.6%	-63.4%	Market data, supplied Oct 15, 2026accession n/a
FY2020	12.4M	-663.9M	-677.6M	-50.24	-861.4M	-5332.9%	-80.0%	Market data, supplied Oct 15, 2026accession n/a
FY2019	14.5M	-582.7M	-1.48B	-112.04	-541.7M	-4014.9%	-166.3%	Market data, supplied Oct 15, 2026accession n/a
FY2018	6.8M	-345.4M	-345.3M	-26.68	-287.1M	-5074.8%	n/m	Market data, supplied Oct 15, 2026accession n/a
FY2017	6.3M	-130.7M	-118.5M	-9.16	-128.5M	-2064.9%	n/m	Market data, supplied Oct 15, 2026accession n/a
FY2016	7.7M	-114.6M	-107.8M	-8.32	-49.3M	-1495.0%	n/m	Market data, supplied Oct 15, 2026accession n/a

Revenue, compound annual growth FY2016 to FY2024: 83.4%
Earnings: Earnings was not positive in both 2016 and 2024, so a compound rate across the window is not defined. Both figures are in the table.
Earnings per share: Earnings per share was not positive in both 2016 and 2021, so a compound rate across the window is not defined. Both figures are in the table.
Free cash flow: Free cash flow was not positive in both 2016 and 2024, so a compound rate across the window is not defined. Both figures are in the table.

Every figure in this section is a line of a filed annual statement or a ratio of two of them. Nothing here is estimated or smoothed. Earnings per share filed before a share split are put on today's share count, and say so. Nothing here is a verdict on the company.

8 of 10

Risks and guardrails

The accounting screens, the published tests, and the lines you can set to be told.

ComputedCompany statement

ASCENTAGE PHARMA GROUP INTERNATIONAL: accounting screens and published tests, each with its source
Figure	Value, source and document
Beneish M-score Why n/a We do not hold this figure for this company, so there is nothing to show.	n/a ComputedFY2024 20-F, filed Apr 16, 2025, 0001213900-25-032599
Piotroski F-score Why n/a We do not hold this figure for this company, so there is nothing to show.	n/a ComputedFY2024 20-F, filed Apr 16, 2025, 0001213900-25-032599
Named tests met	0 of 30 Computed
Beta Why n/a We do not hold this figure for this company, so there is nothing to show.	n/a ComputedClose of Oct 15, 2026

The named tests

Of 30 tests value investors published: 0 met, 7 not met, 23 we could not complete. Counts, never a score: a single figure would have to decide that meeting one investor’s criteria and meeting another’s are worth the same.

Which tests, by name(all 30)

Meets: None of the named tests.
Does not: Large cap, low P/E; High yield, low payout; Dividends and buybacks; Owner earnings yield; High return on tangibles; Low P/S, rising earnings (James O'Shaughnessy); Cash-flow yield and ROIC
Not measured: Defensive investor (Benjamin Graham); Deep value; Earnings yield and ROIC (Joel Greenblatt); High F-score, low P/B (Joseph Piotroski); Three forensic scores; Low PEG, low debt (Peter Lynch); High returns and growth; Gross margin, turnover (Robert Novy-Marx); EV/EBITDA and coverage; Low beta, profitable; ROIC at or above WACC; Near the 52-week low; Z-score and coverage (Edward Altman); Two thirds of NCAV (Benjamin Graham); P/E times P/B (Benjamin Graham); High returns, low debt; Book or below, low debt (Walter Schloss); Cash-covered dividend; Tangible book or below; Clean books, high ROIC; Cheapest quarter on P/E (David Dreman); Cheapest quarter on P/B (David Dreman); Low P/E, growth, yield (John Neff). A test with a figure we could not read is incomplete, never met and never failed.

Figures we could not read(28)

Current Ratio: No annual statement of this kind is on file for this fiscal year.
Debt to Equity: No annual statement of this kind is on file for this fiscal year.
Positive Earnings Streak: The latest filed year has no per-share earnings we can read; the test needs 10.
P/B Ratio: We do not hold this figure for this company, so there is nothing to show.
Piotroski F-Score: We do not hold this figure for this company, so there is nothing to show.
P/E Ratio: Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.
EV/EBIT: We do not hold this figure for this company, so there is nothing to show.
Return on Invested Capital: No annual statement of this kind is on file for this fiscal year.
Altman Z-Score: We do not hold this figure for this company, so there is nothing to show.
Beneish M-Score: We do not hold this figure for this company, so there is nothing to show.
PEG Ratio: Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.
Eps Growth 5Y: We do not hold this figure for this company, so there is nothing to show.
Return on Equity: No annual statement of this kind is on file for this fiscal year.
Asset Turnover: We do not hold this figure for this company, so there is nothing to show.
EV/EBITDA: We do not hold this figure for this company, so there is nothing to show.
Interest Coverage: No operating income line is filed for this year.
Dividend Yield: We do not hold this figure for this company, so there is nothing to show.
Payout Ratio: We do not hold this figure for this company, so there is nothing to show.
Share Count Change Yoy: We do not hold this figure for this company, so there is nothing to show.
Beta: We do not hold this figure for this company, so there is nothing to show.
ROIC-WACC Spread: We do not hold this figure for this company, so there is nothing to show.
Price To Ncav: We do not hold this figure for this company, so there is nothing to show.
Price To Graham: Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.
Return Tangible: We do not hold this figure for this company, so there is nothing to show.
Dividend Coverage Ratio: We do not hold this figure for this company, so there is nothing to show.
Dividend Streak: We do not hold this figure for this company, so there is nothing to show.
Price Tangible Book: We do not hold this figure for this company, so there is nothing to show.
Tangible Equity Ratio: We do not hold this figure for this company, so there is nothing to show.

9 of 10

Declared positions

Whether anybody here owns this company.

Positions declared by the founder: no holding in any company shown here, as of October 3, 2026.

10 of 10

Next step

What to do with what you have read.

Value it in the DCF workbench

A thesis is your reason for owning it, in your words, with the figures that must stay true. Checking those figures every night against the newest filed accounts, and telling you once when one breaks, is what the subscription adds.

What this cannot tell you

28 figures could not be read on this company, among them Current Ratio, Debt to Equity, Positive Earnings Streak. Each blank in the table above names the rest, with its reason. 23 named tests come back incomplete because of them, which is neither met nor missed.
We hold 3 filed fiscal years rather than 10, so the run above is shorter than a full decade and is counted as what it is.

And the one that is true of all of it: This is what the numbers say today. It cannot tell you the day one of them stops being true. Nothing here can, because the reasons are not written down.

Running this once is arithmetic on public documents and you are welcome to it. Writing down why you own each company, in your own words and with the numbers that have to stay true for it to hold, and then having those numbers re-checked every night against the newest filed accounts, and against the latest close where a rule watches a price, is Professional, the plan a new account starts on for 30 days, one trial per person. It writes to you the day one breaks, and stays quiet when nothing does. The check runs every night at 23:30 UTC. A filing is picked up the night after it is published.

Monitor my portfolio How this is computed

No card. 30 free days, and nothing is charged unless you choose a plan.

Analyze your own portfolio

ValueScreener · valuescreener.ai · Computed from accounts filed with the SEC by this company, read from EDGAR, and from dated closing prices. On this page a filed figure opens into its formula, its inputs and the statement, fiscal year and filing date it was read from, and a price into the day of its close. A figure that cannot show that trail says so.

A computation on accounts filed with the SEC, not a recommendation and not advice. Past filings do not indicate future results. Risk disclaimer.

Four questions, at a glance

Quality

Financial strength

Valuation

Cash generation

Revenue and net income, by fiscal year

The reading, in brief

Financial health

Valuation

Companies like ASCENTAGE PHARMA GROUP INTERNATIONAL

The filed figures

Ten years of filed figures

The named tests

What this cannot tell you

Margin Notes